Link to full article April 14, 2022 – Results further support therapeutic potential of Auxora in respiratory diseases and other inflammatory diseases – LA JOLLA, Calif., April 14, 2022 – CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of results from the Company’s CARDEA clinical trial, a Phase […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-05-24 04:29:472022-05-24 04:29:47CalciMedica Announces Publication of Results from CARDEA COVID-19 Study in Critical Care
Link to full article MARINA DEL REY, Calif., May 23, 2022 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the first patient has been dosed in the company’s Phase 1b/2a clinical trial (‘diSArm’) of AP-SA02, which is […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-05-24 04:23:092022-05-24 04:23:09Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
Link to full article Melbourne, Australia – 28 April 2022: Adherium (ASX: ADR), a leader in respiratory eHealth, remote monitoring, and data management solutions, announces the release of the latest Hailie® platform integration tools comprised of an advanced Rest application programming interface (API) and a new, updated software development kit (SDK) to improve connection with […]
Link to full article Melbourne, Australia – 22 April 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce it has significantly strengthened its international commercial leadership team with the appointment of Mr Francis White as Vice President of Global Business Development based in the […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-05-24 04:07:042022-05-24 04:07:04Adherium appoints Vice President of Global Business Development to drive commercial growth
1 April 2022: As leading healthcare investors, BioScience Managers welcomes the on-going bipartisan support for Australia’s developing biotechnology sector following the March Federal Budget. However, BioScience Managers is calling for greater backing from Australia’s investment community, particularly institutional investors, to retain the benefits of Australian innovation within Australia as a critical part our post COVID-19 pandemic recovery. […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-04-04 01:31:132022-04-04 01:31:13BIOSCIENCE MANAGERS CALLS TIME ON THE NEED FOR INVESTORS TO JOIN GOVERNMENT TO BACK AUSTRALIA’S BIOTECH AND DIGITAL INNOVATORS
Link to full article Artarmon, Australia – March 8, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced it received full approval from the United States Food and […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-03-16 03:45:032022-03-16 03:45:03Saluda Medical Receives FDA Approval for the Evoke® Spinal Cord Stimulation System to Treat Chronic Intractable Pain
Link to full article March 10, 2022 Study Supports Development of CRAC Channel Inhibitors for Acute Pancreatitis Study indicates that Orai1 inhibition prevents impaired ductal cell function in acute pancreatitis (AP) Data describes underlying biological mechanisms that may explain key result in a Phase 2a trial of AuxoraTM in patients with AP with systemic inflammatory response […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-03-16 03:20:472022-03-16 03:22:15CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology
27 January 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that that a Decision to Grant a Patent has been received from the Japanese Patent Office (JPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-03-08 04:09:382022-03-08 04:09:38Cynata Receives Decision to Grant a Patent in Japan
29 December 2021: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical stage biotechnology company specialising in cell therapeutics, is pleased to announce the execution of a Manufacturing Services Agreement (“MSA”) with FUJIFILM Cellular Dynamics, Inc (“FCDI”) for the manufacture and supply of Cynata’s Cymerus™ therapeutic mesenchymal stem cell (“MSC”) products derived from induced pluripotent […]
22 December 2021: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical stage biotechnology company specialising in cell therapeutics, is pleased to announce its clinical trial of CYP-006TK in patients with diabetic foot ulcers (DFU) has commenced and is now open for patient enrolment. The Phase I trial (protocol number CYP-DFU-P1-01) aims to recruit 30 […]
CalciMedica Announces Publication of Results from CARDEA COVID-19 Study in Critical Care
/in Calcimedica, UncategorisedLink to full article April 14, 2022 – Results further support therapeutic potential of Auxora in respiratory diseases and other inflammatory diseases – LA JOLLA, Calif., April 14, 2022 – CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of results from the Company’s CARDEA clinical trial, a Phase […]
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
/in Armata Pharmaceuticals, UncategorisedLink to full article MARINA DEL REY, Calif., May 23, 2022 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the first patient has been dosed in the company’s Phase 1b/2a clinical trial (‘diSArm’) of AP-SA02, which is […]
Adherium Releases Next Generation Respiratory Platform Integration Services
/in Adherium, UncategorisedLink to full article Melbourne, Australia – 28 April 2022: Adherium (ASX: ADR), a leader in respiratory eHealth, remote monitoring, and data management solutions, announces the release of the latest Hailie® platform integration tools comprised of an advanced Rest application programming interface (API) and a new, updated software development kit (SDK) to improve connection with […]
Adherium appoints Vice President of Global Business Development to drive commercial growth
/in Adherium, UncategorisedLink to full article Melbourne, Australia – 22 April 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce it has significantly strengthened its international commercial leadership team with the appointment of Mr Francis White as Vice President of Global Business Development based in the […]
BIOSCIENCE MANAGERS CALLS TIME ON THE NEED FOR INVESTORS TO JOIN GOVERNMENT TO BACK AUSTRALIA’S BIOTECH AND DIGITAL INNOVATORS
/in BioSciences Managers, Industry News, Uncategorised1 April 2022: As leading healthcare investors, BioScience Managers welcomes the on-going bipartisan support for Australia’s developing biotechnology sector following the March Federal Budget. However, BioScience Managers is calling for greater backing from Australia’s investment community, particularly institutional investors, to retain the benefits of Australian innovation within Australia as a critical part our post COVID-19 pandemic recovery. […]
Saluda Medical Receives FDA Approval for the Evoke® Spinal Cord Stimulation System to Treat Chronic Intractable Pain
/in BioSciences Managers, Saluda Medical, UncategorisedLink to full article Artarmon, Australia – March 8, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced it received full approval from the United States Food and […]
CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology
/in BioSciences Managers, Calcimedica, UncategorisedLink to full article March 10, 2022 Study Supports Development of CRAC Channel Inhibitors for Acute Pancreatitis Study indicates that Orai1 inhibition prevents impaired ductal cell function in acute pancreatitis (AP) Data describes underlying biological mechanisms that may explain key result in a Phase 2a trial of AuxoraTM in patients with AP with systemic inflammatory response […]
Cynata Receives Decision to Grant a Patent in Japan
/in BioSciences Managers, Cynata, Uncategorised27 January 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that that a Decision to Grant a Patent has been received from the Japanese Patent Office (JPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application […]
Cynata and FUJIFILM Cellular Dynamics Execute Strategic Manufacturing Agreement
/in BioSciences Managers, Cynata, Uncategorised29 December 2021: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical stage biotechnology company specialising in cell therapeutics, is pleased to announce the execution of a Manufacturing Services Agreement (“MSA”) with FUJIFILM Cellular Dynamics, Inc (“FCDI”) for the manufacture and supply of Cynata’s Cymerus™ therapeutic mesenchymal stem cell (“MSC”) products derived from induced pluripotent […]
Cynata Commences DFU Clinical Trial
/in BioSciences Managers, Cynata, Uncategorised22 December 2021: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical stage biotechnology company specialising in cell therapeutics, is pleased to announce its clinical trial of CYP-006TK in patients with diabetic foot ulcers (DFU) has commenced and is now open for patient enrolment. The Phase I trial (protocol number CYP-DFU-P1-01) aims to recruit 30 […]